AUPH Stock Summary and Trading Ideas (Aurinia Pharmaceuticals - Common Shares | NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.

As of April 18, 2024, AUPH stock price declined to $4.81 with 2,030,244 million shares trading.

AUPH has a beta of 1.99, meaning it tends to be more sensitive to market movements. AUPH has a correlation of 0.15 to the broad based SPY ETF.

AUPH has a market cap of $695.61 million. This is considered a Small Cap stock.

Last quarter Aurinia Pharmaceuticals - Common Shares reported $45 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $645,000 and missed earnings estimates by -$.03.

In the last 3 years, AUPH stock traded as high as $33.97 and as low as $4.07.

The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, VHT.

AUPH has underperformed the market in the last year with a price return of -55.3% while the SPY ETF gained +22.3%. AUPH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.9% and -7.1%, respectively, while the SPY returned +6.1% and -3.8%, respectively.

AUPH support price is $4.77 and resistance is $5.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH stock will trade within this expected range on the day.